

Leishmaniasis

SOMALIA

2014

Published in July 2016
Updated in September 2016

Country General Information (WHO, 2013)

Total population:	10,496,000	Age group <15/>14 years, %:	47% / 53%
Gender (% F/M):	50.3% / 49.7%	Life expectancy at birth in years (F/M):	53 / 56
GDP (PPP int \$):	1399	Number of 2nd sub-national administrative level divisions, name:	90, District
Income status:	Low		

Epidemiology


	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Non-endemic	Non-endemic	Non-endemic
Number of new cases (incidence):	1043	N/A	N/A	N/A
Number of relapse cases:	2	N/A	N/A	N/A
Total number of cases:	1045	N/A	N/A	N/A
Imported cases (n, %):	No data	No data	No data	No data
Gender distribution (% F):	39%	N/A	N/A	N/A
Age group distribution (% , <5/5-14/>14):	(56/36/8)	N/A	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	4.12	N/A	N/A	N/A
Number of endemic 2nd sub-national administrative level divisions for VL or CL (#):	100	N/A	N/A	N/A
Population at risk ¹ (% , n/total):	24% (2538052/10496000)	N/A	N/A	N/A
Was there any outbreak?	Not available	N/A	N/A	N/A
Number of new ² foci:	Not available	N/A	N/A	N/A

N/A = not applicable VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis MCL = mucocutaneous leishmaniasis

Monthly distribution of new cases January-December


2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	84	101	82	101	94	127	118	61	71	75	44	87
CL	0	0	0	0	0	0	0	0	0	0	0	0

Number of new (primary) VL cases reported by month in 2013 and 2014, Somalia



Incidence rate/10 000 and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014

Not endemic for CL



¹ Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

* Data not available


² For this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever

³ Incidence rate at the national level

Distribution of new CL (left) and new (primary) VL (right) cases

Not endemic for CL

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production:
WHO/HTM/NTD/IDM



* Cases were reported from Bossaso General Hospital in Bari region in 2014 but the actual provenance of the cases was not recorded. They were therefore all attributed to Bossaso district on this map to show that VL cases have been reported from this region.

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available	Year latest national guidelines were published:	2012
Type of surveillance:	Other	Is leishmaniasis a notifiable disease (mandatory reporting)?	No
Is there a vector control programme?	No	Is there a reservoir host control programme?	No
Type of insecticide used for IRS:	N/A	Number of leishmaniasis health facilities:	3

Diagnosis

	VL	CL	PKDL	MCL
Number of people screened actively for:	0	N/A	N/A	N/A
Number of people screened passively for:	323 ^a	N/A	N/A	N/A
VL cases diagnosed by RDT* (%, # RDT+/total VL cases):	65% (682/1043)	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	76% (682/899)	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (%, # slides +/total cases):	0% (0/1043)	N/A	N/A	N/A
Proportion of positive slides (%, # slides +/total slides):	N/A	N/A	N/A	N/A
Cases diagnosed clinically (%, # clinical cases/total cases):	34% (351/1045)	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

* These indicators apply only for primary VL cases

VL = visceral leishmaniasis CL = cutaneous leishmaniasis

PKDL = post-kala-azar dermal leishmaniasis

N/A = not applicable

RDT = rapid diagnostic test HIV = human immunodeficiency virus

MCL = mucocutaneous leishmaniasis

^a Data from only 1 health facility

Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Sodium stibogluconate (SSG)

TREATMENT OUTCOME

	VL	
Proportion of relapse cases: ⁴	0.2%	(2/1045)
Initial cure rate:	No data	
Failure ⁵ rate:	No data	
Case-fatality rate:	3%	(29/1045)

⁴ A relapse case in this country is defined as:

A patient who has completed a full treatment course, or at least 15 days with an appropriate amount of antimonials as single therapy more than one month ago and then returns with proven kala-azar. Relapses are diagnosed parasitologically.

Data source: Ministry of Health, Somalia
© WHO 2014. All rights reserved.

⁵ A failure case in this country is defined as:

A patient who does not respond favourably during the first 2 weeks of treatment with SSG.